Literature DB >> 23332546

Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU.

Fernando Gomollón1, Santiago García-López, Beatriz Sicilia, Javier P Gisbert, Joaquín Hinojosa.   

Abstract

BACKGROUND AND AIM: Evidence-based clinical guidelines on Ulcerative colitis (UC) have been developed through a consensus, while GRADE methodology is the current standard for guideline development. This is the first one based on GRADE methodology on UC.
METHODS: Following GRADE methodology, the Spanish Group of Ulcerative Colitis and Crohn's disease (GETECCU) have developed a guideline on UC treatment. After selection of relevant clinical scenarios, 32 clinical questions were chosen and recommendations were established.
RESULTS: In 2 questions no recommendation was possible. Twenty-two actions were recommended for, 14 strongly and 8 weakly. However, in 8 questions a recommendation against doing something was obtained, weak in 5 and strong in 3. The majority of recommendations were based on moderate quality evidence, and only 5 on high-quality evidence.
CONCLUSIONS: With GRADE methodology we find a clear recommendation on possible actions in most clinical decisions in UC treatment, but much more clinical high-quality research is needed.
Copyright © 2012 Elsevier España, S.L. and AEEH y AEG. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23332546     DOI: 10.1016/j.gastrohep.2012.09.006

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  7 in total

1.  Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis?

Authors:  Javier P Gisbert; María Chaparro
Journal:  United European Gastroenterol J       Date:  2019-09-27       Impact factor: 4.623

Review 2.  Second Korean guidelines for the management of ulcerative colitis.

Authors:  Chang Hwan Choi; Won Moon; You Sun Kim; Eun Soo Kim; Bo-In Lee; Yunho Jung; Yong Sik Yoon; Heeyoung Lee; Dong Il Park; Dong Soo Han
Journal:  Intest Res       Date:  2017-01-31

3.  Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma.

Authors:  Milan Jovanovic; Nevena Gajovic; Natasa Zdravkovic; Marina Jovanovic; Milena Jurisevic; Danilo Vojvodic; Veljko Maric; Aleksandar Arsenijevic; Ivan Jovanovic
Journal:  Mediators Inflamm       Date:  2018-04-04       Impact factor: 4.711

4.  Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study.

Authors:  Beatriz Sicilia; Lara Arias; Gadea Hontoria; Nieves García; Ester Badia; Fernando Gomollón
Journal:  Front Med (Lausanne)       Date:  2021-06-25

5.  Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.

Authors:  B Jharap; W J Sandborn; W Reinisch; G D'Haens; A M Robinson; W Wang; B Huang; A Lazar; R B Thakkar; J-F Colombel
Journal:  Aliment Pharmacol Ther       Date:  2015-09-03       Impact factor: 8.171

6.  Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution.

Authors:  David Díaz-Jiménez; Marjorie De la Fuente; Karen Dubois-Camacho; Glauben Landskron; Janitza Fuentes; Tamara Pérez; María Julieta González; Daniela Simian; Marcela A Hermoso; Rodrigo Quera
Journal:  BMC Gastroenterol       Date:  2016-08-26       Impact factor: 3.067

7.  Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression.

Authors:  Marina Jovanovic; Bojana Simovic Markovic; Nevena Gajovic; Milena Jurisevic; Aleksandar Djukic; Ivan Jovanovic; Nebojsa Arsenijevic; Aleksandra Lukic; Natasa Zdravkovic
Journal:  World J Gastroenterol       Date:  2019-11-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.